SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 16, 2003
EPIX Medical, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-21863 |
|
04-3030815 |
|
(State or other |
|
(Commission |
|
(IRS Employer |
71 Rogers Street
Cambridge, Massachusetts 02142
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 250-6000
Item 5. Other Events.
On December 16, 2003, Epix Medical, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MS-325, a contrast agent designed specifically for vascular imaging with magnetic resonance angiography (MRA). MS-325 is being co-developed by EPIX and Schering AG, Germany. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) The following exhibits are furnished with this report:
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated December 16, 2003. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
EPIX Medical, Inc. |
||
|
|
(Registrant) |
||
|
|
|
|
|
|
|
|
|
|
|
Date: December 16, 2003 |
/s/ |
Peyton J. Marshall |
|
|
|
|
Peyton J. Marshall |
|
|
|
|
Senior Vice-President, |
|
|
|
|
Finance and Administration, |
|
|
|
|
Chief Financial Officer |
|
3